Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Neurobiol Dis. 2014 May 10;72PA:117–122. doi: 10.1016/j.nbd.2014.05.001

Figure 1.

Figure 1

From Jack et al. (2012): Changes in AD biomarker data on the vertical axis vs. AD clinical stage, with preclinical staging highlighted in yellow Each biomarker is scaled from maximally normal (bottom) to maximally abnormal (top) with PET amyloid imaging (red line), biomarkers of neurodegeneration are FDG-PET or atrophy on MRI (blue line), and cognitive (purple line).